AU6633186A - Construction of an IgG binding protein to facilitate downstream processing using protein engineering - Google Patents

Construction of an IgG binding protein to facilitate downstream processing using protein engineering

Info

Publication number
AU6633186A
AU6633186A AU66331/86A AU6633186A AU6633186A AU 6633186 A AU6633186 A AU 6633186A AU 66331/86 A AU66331/86 A AU 66331/86A AU 6633186 A AU6633186 A AU 6633186A AU 6633186 A AU6633186 A AU 6633186A
Authority
AU
Australia
Prior art keywords
recombinant dna
protein
sequence
fragment
dna molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU66331/86A
Other versions
AU600244B2 (en
Inventor
Lars Abrahamsen
Tomas Moks
Bjorn Nilsson
Mathias Uhlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Kabigen AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabigen AB filed Critical Kabigen AB
Publication of AU6633186A publication Critical patent/AU6633186A/en
Application granted granted Critical
Publication of AU600244B2 publication Critical patent/AU600244B2/en
Assigned to KABI PHARMACIA AB reassignment KABI PHARMACIA AB Alteration of Name(s) in Register under S187 Assignors: KABIGEN AB
Assigned to PHARMACIA AB reassignment PHARMACIA AB Alteration of Name(s) in Register under S187 Assignors: KABI PHARMACIA AB
Assigned to PHARMACIA & UPJOHN AB reassignment PHARMACIA & UPJOHN AB Request to Amend Deed and Register Assignors: PHARMACIA AB
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A recombinant DNA fragment (Z) coding for an immuno­globulin G binding domain related to staphylococcal protein A, characterized in that the methionine codon of said fragment has been replaced by a codon of another amino acid residue enabling expression of a methionine­free protein;a recombinant DNA sequence comprising at least two such fragments;a recombinant DMA sequence comprising such fragment preceded by a signal sequence and followed by a nucleotide sequence coding for the amino acid se­quence:Ala Gln His Asp Glu Ala;a recombinant DNA molecule comprising such recombinant DNA sequence and fused 3ʹ thereof at DNA level a pro­duction gene, said molecule having the ability to express a fused protein;a process for cleaving a fused protein expressed in a biological system by a such recombinant DNA molecule;a plasmid vector comprising said recombinant DNA molecule; anda bacterial cell harbouring such recombinant DNA molecule.
AU66331/86A 1985-12-13 1986-12-09 Construction of an IgG binding protein to facilitate downstream processing using protein engineering Ceased AU600244B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8505922A SE8505922D0 (en) 1985-12-13 1985-12-13 CONSTRUCTION OF AN IGG BINDING PROTEIN TO FACILITATE DOWNSTREAM PROCESSING USING PROTEIN ENGINEERING
SE8505922 1985-12-13

Publications (2)

Publication Number Publication Date
AU6633186A true AU6633186A (en) 1987-06-18
AU600244B2 AU600244B2 (en) 1990-08-09

Family

ID=20362468

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66331/86A Ceased AU600244B2 (en) 1985-12-13 1986-12-09 Construction of an IgG binding protein to facilitate downstream processing using protein engineering

Country Status (11)

Country Link
US (1) US5143844A (en)
EP (1) EP0230869B1 (en)
JP (1) JPH0811069B2 (en)
AT (1) ATE80180T1 (en)
AU (1) AU600244B2 (en)
CA (1) CA1311430C (en)
DE (1) DE3686646T2 (en)
DK (1) DK600486A (en)
ES (1) ES2046177T3 (en)
GR (1) GR3006178T3 (en)
SE (1) SE8505922D0 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597317B2 (en) * 1985-12-13 1990-05-31 Pharmacia & Upjohn Ab A method to export gene products to the growth medium of gram negative bacteria
AU598423B2 (en) * 1985-11-15 1990-06-21 Novo Nordisk A/S Peptides and compositions
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601940D0 (en) * 1986-04-25 1986-04-25 Kabigen Ab PREPARATION OF FUSED PROTEINS, ANTIBODIES AND PROCESSES THEREFOR
US5985599A (en) * 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
US5095096A (en) * 1987-05-29 1992-03-10 Sagami Chemical Research Center Fused protein comprising lymphotoxin
AU623361B2 (en) * 1987-11-20 1992-05-14 Creative Biomolecules, Inc. Selective removal of immune complexes
US5243040A (en) * 1987-11-20 1993-09-07 Creative Biomolecules DNA encoding a protein which enables selective removal of immune complexes
US5084398A (en) * 1987-11-20 1992-01-28 Creative Biomolecules Selective removal of immune complexes
SE8800981A (en) * 1988-03-17 1988-10-14 Lars Abrahamsen A RECOMBINANT FUSION PROTEIN, ITS USE AND A RECOMBINANT VECTOR
SE509359C2 (en) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Use of stabilized protein or peptide conjugates for the preparation of a drug
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5595887A (en) * 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
US6077694A (en) * 1990-09-21 2000-06-20 The United States Of America As Represented By The Department Of Health And Human Services Method for over-expression and rapid purification of biosynthetic proteins
US5863783A (en) * 1991-03-27 1999-01-26 Gist-Brocades, N.V. Cloning and expression of DNA molecules encoding arabinan-degrading enzymes of fungal origin
AU2368892A (en) * 1991-07-29 1993-03-02 British Bio-Technology Limited Igf-ii analogues
US5989887A (en) * 1992-11-25 1999-11-23 Dsm N.V. Cloning and expression of DNA molecules incoding arabinan-degrading enzymes of fungal origin
SE9504019D0 (en) * 1995-11-13 1995-11-13 Pharmacia Ab Method for production of proteins
US5917026A (en) * 1996-02-05 1999-06-29 Loewenadler; Bjoern Fusion proteins of immunopotentiating activity
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
WO1998011913A1 (en) * 1996-09-16 1998-03-26 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU762047B2 (en) 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
JP3971108B2 (en) 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド Insulin-like growth factor (IGF) I mutant
IL145597A0 (en) 1999-04-08 2002-06-30 Genentech Inc Composition based on oppositely-charged polypeptides
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
SE0200943D0 (en) 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US20050003548A1 (en) * 2002-07-22 2005-01-06 Nikolay Korokhov Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof
ES2541673T3 (en) 2003-09-12 2015-07-23 Ipsen Biopharmaceuticals, Inc. Methods for the treatment of insulin-like growth factor 1 deficiency (IGF-1)
JP2007537711A (en) 2003-10-03 2007-12-27 ジェネンテック・インコーポレーテッド IGF binding protein
JP5634008B2 (en) 2004-04-06 2014-12-03 アフィボディ・アーベー New uses and methods
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
JP5808070B2 (en) 2005-12-02 2015-11-10 ジェネンテック， インコーポレイテッド Binding polypeptides and uses thereof
JP2008048607A (en) 2006-08-22 2008-03-06 Chisso Corp FUSION PROTEIN OF Fc-BINDING DOMAIN AND CALCIUM-BINDING PHOTOPROTEIN, GENE ENCODING THE SAME AND USE THEREOF
GB2442118B (en) 2006-09-19 2011-08-17 Chisso Corp Process for production of recombinant proteins as a soluble form
WO2008127457A2 (en) 2006-12-06 2008-10-23 Repligen Corporation Nucleic acids encoding recombinant protein a
US8198043B2 (en) * 2006-12-08 2012-06-12 General Electric Company Two helix binders
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
WO2010110288A1 (en) 2009-03-24 2010-09-30 株式会社カネカ Protein having affinity for immunoglobulin, and immunoglobulin-binding affinity ligand
KR101431318B1 (en) 2009-04-02 2014-08-20 로슈 글리카트 아게 Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG10201408401RA (en) 2009-09-16 2015-01-29 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
CN102811782A (en) * 2010-03-08 2012-12-05 通用电气健康护理生物科学股份公司 Immunoglobulin g fc region binding polypeptide
SG184184A1 (en) 2010-03-24 2012-10-30 Kaneka Corp Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
EP2560683B2 (en) 2010-04-23 2022-07-20 F. Hoffmann-La Roche AG Production of heteromultimeric proteins
KR20130100125A (en) 2010-08-13 2013-09-09 제넨테크, 인크. Antibodies to il-1beta and il-18, for treatment of disease
JP5758004B2 (en) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Bispecific antibodies comprising Fv fragments stabilized by disulfides
US9683013B2 (en) 2010-12-20 2017-06-20 Ge Healthcare Bioprocess R&D Ab Affinity chromatography matrix
JP5974343B2 (en) 2010-12-20 2016-08-23 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ Affinity chromatography matrix
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
EP2670776B1 (en) 2011-02-04 2018-11-21 F. Hoffmann-La Roche AG Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
SG193950A1 (en) 2011-03-25 2013-11-29 Kaneka Corp Novel immunoglobulin-binding polypeptide
SG10201604559TA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
SI2766397T1 (en) 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Improved assembly of bispecific antibodies
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
JP6420756B2 (en) * 2012-03-28 2018-11-07 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ Affinity chromatography matrix
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
MX354862B (en) 2012-06-27 2018-03-23 Hoffmann La Roche Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof.
WO2015005859A1 (en) 2013-07-10 2015-01-15 Ge Healthcare Bio-Sciences Ab Mutated immunoglobulin-binding polypeptides
US10221211B2 (en) 2013-09-27 2019-03-05 Kaneka Corporation Process for producing porous cellulose beads using alkali aqueous solution
EP3140392B1 (en) 2014-05-06 2023-07-26 F. Hoffmann-La Roche AG Production of heteromultimeric proteins using mammalian cells
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107001482B (en) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 Multispecific antibodies
WO2016121701A1 (en) 2015-01-26 2016-08-04 株式会社カネカ AFFINITY SEPARATION MATRIX FOR PURIFYING PROTEIN CONTAINING IMMUNOGLOBULIN κ CHAIN VARIABLE REGION
CN108064286A (en) 2015-01-26 2018-05-22 株式会社钟化 Saltant type immunoglobulin kappa chain variable region binding peptide
JP6424101B2 (en) * 2015-01-30 2018-11-14 Jnc株式会社 Fusion protein of Fc-binding domain and calcium-binding photoprotein, gene encoding the same, and use thereof
WO2016125811A1 (en) 2015-02-05 2016-08-11 三菱化学株式会社 Protein having affinity to immunoglobulin, and affinity separation medium and column for liquid chromatography using same
WO2017195638A1 (en) 2016-05-09 2017-11-16 株式会社カネカ Method for refining antibody or antibody fragment containing κ-chain variable region
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109071613A (en) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 Isolation medium
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455240A1 (en) 2016-05-11 2019-03-20 GE Healthcare BioProcess R&D AB Method of storing a separation matrix
US11779860B2 (en) 2017-08-07 2023-10-10 Repligen Corporation Fc binding proteins with cysteine in the C-terminal helical region
GB202018588D0 (en) 2020-11-26 2021-01-13 Cytiva Bioprocess R & D Ab Separation matrix
GB202113626D0 (en) 2021-09-24 2021-11-10 Cytiva Bioprocess R & D Ab FC binding polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
SE8300693L (en) * 1983-02-09 1984-08-10 Sven Lofdahl SET TO MAKE AND ISOLATE PROTEINS AND POLYPEPTIDES, AND A HYBRID VECTOR FOR THIS

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598423B2 (en) * 1985-11-15 1990-06-21 Novo Nordisk A/S Peptides and compositions
AU597317B2 (en) * 1985-12-13 1990-05-31 Pharmacia & Upjohn Ab A method to export gene products to the growth medium of gram negative bacteria
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins

Also Published As

Publication number Publication date
EP0230869A3 (en) 1988-08-03
CA1311430C (en) 1992-12-15
ES2046177T3 (en) 1994-02-01
AU600244B2 (en) 1990-08-09
GR3006178T3 (en) 1993-06-21
JPS62190087A (en) 1987-08-20
DK600486D0 (en) 1986-12-12
JPH0811069B2 (en) 1996-02-07
EP0230869A2 (en) 1987-08-05
SE8505922D0 (en) 1985-12-13
DK600486A (en) 1987-06-14
DE3686646T2 (en) 1993-04-08
DE3686646D1 (en) 1992-10-08
US5143844A (en) 1992-09-01
ATE80180T1 (en) 1992-09-15
EP0230869B1 (en) 1992-09-02

Similar Documents

Publication Publication Date Title
AU6633186A (en) Construction of an IgG binding protein to facilitate downstream processing using protein engineering
Misra et al. Mercuric ion-resistance operons of plasmid R100 and transposon Tn501: the beginning of the operon including the regulatory region and the first two structural genes.
Kodaira et al. The dnaX gene encodes the DNA polymerase III holoenzyme τ subunit, precursor of the γ subunit, the dnaZ gene product
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
Roeder et al. Cloning the trpR gene
EP1757689A3 (en) Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
Groarke et al. The amino acid sequence of D-ribose-binding protein from Escherichia coli K12.
JPS57181099A (en) Bacillus cloning vector, recombinant dna molecule, bacillus host transformed thereby and manufacture of polypeptide expressing dna order and being coded thereby
EP1559776A3 (en) Non-toxic, non-toxigenic, non-pathogenic Fusarium expression system and promoters and terminators for use therein
WO1995016048A3 (en) Recombinant protein production in bovine adenovirus expression vector system
IL57491A (en) Recombinant dna,methods for the production thereof and proteins or polypeptides produced thereby
HK1013847A1 (en) Gdf-1 and uog-1 proteins
AU5233686A (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
EP0737747A3 (en) Cytoplasmatic expression in E. coli of antibodies, antibody fragments and fusions thereof
Tian et al. Gene Product Identification and Promoter Analysis ofhigLocus of Plasmid Rts1
JPS6420095A (en) Polypeptide having anti-blood coagulating action
HUT52551A (en) Process for production of neutrophil-activizating factor
Sarvas et al. A precursor form of the penicillinase from Bacillus licheniformis
EP0805204A3 (en) Epididymis-specific receptor protein and its use
DE3572843D1 (en) Site-specific proteolysis by renin
ZA9610456B (en) N-terminally extended proteins expressed in yeast
Taylor et al. Similarities in the heavy and light chains of tetanus toxin suggested by their amino acid compositions
Thomann et al. Homologous expression and purification of mutants of an essential protein by reverse epitope-tagging
EP0422217A4 (en) Human recombinant placental ribonuclease inhibitor and method of production
AU6252294A (en) A mutant protein and methods and materials for making and using it